Coya Therapeutics, Inc.
Business
Coya Therapeutics is a clinical-stage biotechnology company developing proprietary biologics and cell therapies to enhance the function of regulatory T cells (Tregs) for neurodegenerative, autoimmune, and metabolic diseases. The company's lead program, COYA 302, is a biologic combination of low-dose IL-2 and CTLA4-Ig in Phase 2 trials for amyotrophic lateral sclerosis and frontotemporal dementia. Coya also develops Treg-derived exosomes and autologous Treg cell therapies through multiple therapeutic modalities.
Summary from 10-K filed 2026-03-16
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 8 | 4 | 6 | 0 | — | |
| Research and development | 17 | 12 | 6 | 4 | 3 | |
| In-process research and development | 2 | 25,000 | 543,186 | 525,000 | — | |
| General and administrative | 11 | 9 | 8 | 5 | 2 | |
| Depreciation | 27,361 | 27,361 | 27,361 | 27,361 | 16,133 | |
| Total operating expenses | 31 | 21 | 14 | 10 | 5 | |
| Loss from operations | −23 | −17 | −8 | −10 | −5 | |
| Other income | 1 | 2 | 639,365 | 63,673 | −21,482 | |
| Pre-tax loss | −21 | −16 | −7 | −12 | — | |
| Income tax (expense) benefit | −3,089 | 700,000 | −723,852 | 0 | — | |
| Net loss | −21 | −15 | −8 | −12 | −5 | |
| Net loss per share of common stock, basic | −1.27 | −0.98 | −0.79 | −4.73 | −1.89 | |
| Net loss per share of common stock, diluted | −1.27 | −0.98 | −0.79 | −4.73 | −1.89 | |
| Weighted-average shares of common stock outstanding, basic | 17 | 15 | 10 | 3 | 3 | |
| Weighted-average shares of common stock outstanding, diluted | 17 | 15 | 10 | 3 | 3 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 47 | 38 | 33 | 6 | 4 | |
| Prepaids and other current assets | 3 | 6 | 1 | 1 | 244,080 | |
| Total current assets | 50 | 44 | 41 | 7 | 5 | |
| Fixed assets, net | 11,227 | 38,588 | 65,949 | 93,310 | 120,671 | |
| Total assets | 50 | 44 | 41 | 8 | 5 | |
| Accounts payable | 1 | 2 | 1 | 2 | 857,567 | |
| Accrued expenses | 4 | 1 | 3 | 2 | 290,816 | |
| Deferred collaboration revenue | 1 | 848,286 | 923,109 | — | — | |
| Total current liabilities | 6 | 4 | 5 | 4 | 1 | |
| Deferred collaboration revenue | 1 | 945,447 | 574,685 | — | — | |
| Total liabilities | 7 | 5 | 6 | 17 | 1 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued and outstanding as of December 31, 2025 and 2024 | — | — | — | 9 | 9 | |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 20,934,456 and 16,707,441 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2,094 | 1,671 | 1,441 | 259 | 259 | |
| Additional paid-in capital | 105 | 80 | 62 | 681,106 | 473,602 | |
| Accumulated deficit | −62 | −41 | −26 | −18 | −6 | |
| Total stockholders' equity | 43 | 40 | 36 | −8 | 4 | |
| Total liabilities and stockholders' equity | 50 | 44 | 41 | 8 | 5 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −21 | −15 | −8 | −12 | −5 | |
| Stock-based compensation, including the issuance of restricted stock | 4 | 3 | 872,248 | 207,346 | 233,222 | |
| Collaboration receivable | — | 8 | −8 | — | — | |
| Prepaids and other current assets | 3 | −5 | 181,707 | −920,002 | −216,813 | |
| Accounts payable | −527,006 | 477,450 | 298,816 | 845,284 | 665,166 | |
| Accrued expenses | 1 | −1 | 877,913 | 826,556 | 290,816 | |
| Deferred collaboration revenue | 454,247 | 295,939 | 1 | — | — | |
| Net cash used in operating activities | −11 | −10 | −11 | −7 | −4 | |
| Purchase of in-process research and development assets | −1 | −25,000 | −543,186 | −525,000 | — | |
| Net cash used in investing activities | −1 | −25,000 | −543,186 | −525,000 | −136,804 | |
| Proceeds from sale of common stock, net of offering costs | 20 | 14 | — | — | — | |
| Payment of financing costs related to the 2023 Private Placement | — | −131,918 | — | — | — | |
| Proceeds from subscription receivable | — | 11,250 | — | — | — | |
| Proceeds from the exercise of stock options | 38,274 | 1,975 | 89,947 | 158 | 317 | |
| Proceeds from the exercise of warrants | — | 2 | — | — | — | |
| Net cash provided by financing activities | 20 | 16 | 38 | 9 | −340,584 | |
| Net increase in cash and cash equivalents | 8 | 6 | 27 | 2 | −4 | |
| In process research and development costs in accrued expenses | 1 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Coya Therapeutics, Inc.'s CIK number?
Coya Therapeutics, Inc.'s SEC CIK number is 0001835022 (1835022). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Coya Therapeutics, Inc.'s SEC filings?
All of Coya Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Coya Therapeutics, Inc. last report earnings?
Coya Therapeutics, Inc. (COYA) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-218198). This is Coya Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Coya Therapeutics, Inc.'s most recent earnings 8-K?
Coya Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-218198. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Coya Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →